NCT07335861 Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 122 participants in total. It began in 2026-05-14 with a primary completion date of 2026-12-31.

Brief Summary

This is a randomized controlled trial evaluating the efficacy of HYALOMATRIX in conjunction with standard of care vs. standard of care alone in treating venous leg ulcers.

Eligibility Criteria

Inclusion Criteria: 1. Male or Female, 18 years of age or older 2. Subject has a medical diagnosis of venous leg ulcer or venous insufficiency with a lower extremity wound 3. Subject has a venous leg ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC 4. Subject has a venous leg ulcer with a historical wound measurement showing less than 25% healing within 14 days prior to screening 5. Subject has a venous leg ulcer with screening wound measurement showing less than 25% healing within 14 days prior to randomization 6. Subject has a venous leg ulcer without infection or clinically visible exposed bone 7. Index wound is a minimum of 1 cm2 and a maximum of 30 cm2 at first treatment visit 8. Adequate circulation if wound is location on the lower extremity demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to informed consent OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to the first treatment visit. 9. Venous Leg Ulcer is being treated with compression therapy for 14 days prior to treatment visit 1 10. Index wound is free of necrotic debris prior to Hyalomatrix application 11. Female subjects of childbearing potential having a negative pregnancy test prior to randomization 12. Index wound is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization. 13. Subject is able and willing to follow the protocol requirements 14. Subject had signed informed consent 15. If 2 or more wounds are present, the wounds must be separated by at least 2 cm Exclusion Criteria: 1. Subject does not have a diagnosis of venous leg ulcer or venous insufficiency with a wound located on the lower extremity 2. Subject has a known life expectancy of \<1 year 3. Subject is unable to comply with protocol treatment 4. Subject has comorbid conditions that may compromise subject safety or wound healing in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders 5. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound 6. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator 7. Known contraindications to tissue-engineered allograft 8. Concurrent participation in alternative clinical trial that involves investigational drug or HCT/P interfering with wound treatment and/or healing. 9. Subject is pregnant or breastfeeding 10. Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for \>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study 11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization 12. Venous leg ulcer with active infection 13. Wound depth with visible exposed bone 14. HBOT within 14 days prior to randomization 15. Revascularization surgery on the index wound leg within 30 days of screening phase 16. Index wound suspicious of neoplasm in the opinion of the principal investigator

Contact & Investigator

Frequently Asked Questions

Related Trials